ArticleTranslational lung cancer research2025
Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). However, their efficacy and safety in patients with idiopathic interstitial pneumonias (IIPs) or interstitial lung abnormalities (ILAs) remain poorly defined, as such patients have been largely excluded from pivotal clinical trials. This study aimed to assess real-world outcomes and adverse events associated with ICI-based therapies in patients with NSCLC and coexisting IIPs or ILAs. Methods: We conducted a multicenter retrospective cohort study across 11 institutions affiliated with the North Japan Lung Cancer Study Group. Patients with advanced NSCLC and pre-existing IIPs or ILAs who received ICI monotherapy or ICI plus chemotherapy (chemo-ICI) between December 2015 and March 2020 were included. Data on progression-free survival (PFS), overall survival (OS), treatment response, and pneumonitis incidence were collected. High-resolution computed tomography (HRCT) images were centrally reviewed to classify the radiologic patterns of IIPs and ILAs. Results: A total of 53 patients with IIPs and 18 with ILAs were analyzed. In the IIP cohort, the median PFS was 5.1 months with chemo-ICI, 7.3 months with first-line ICI monotherapy, and 5.7 months with second-line or later ICI monotherapy. The median OS ranged from 5.4 to 15.4 months, depending on the treatment type. Grade 3-4 pneumonitis occurred in 17.0% of patients with IIPs. In the ILA cohort, chemo-ICI resulted in a median OS of 27.0 months with no cases of pneumonitis, while ICI monotherapy was associated with a 22.2% pneumonitis incidence. Subpleural fibrotic ILAs were linked to a higher risk of pneumonitis. Long-term survivors were identified in both cohorts. Conclusions: ICI therapy may provide durable survival benefits for patients with NSCLC and underlying IIPs or ILAs. However, the elevated incidence of high-grade pneumonitis-particularly in patients with IIPs or fibrotic ILAs-underscores the importance of careful patient selection. Prospective studies are needed to refine treatment strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.